help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on October 21, 2004
Endocrinology, doi:10.1210/en.2004-1116
A more recent version of this article appeared on February 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
146/2/825    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MASUDA, S.
Right arrow Articles by JONES, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MASUDA, S.
Right arrow Articles by JONES, G.

Submitted on August 23, 2004
Accepted on October 14, 2004

Altered Pharmacokinetics of 1{alpha},25-Dihydroxyvitamin D3 and 25-Hydroxyvitamin D3 in the Blood and Tissues of the 25-Hydroxyvitamin D-24-Hydroxylase (Cyp24a1) Null Mouse*

SONOKO MASUDA, VALARIE BYFORD, ALICE ARABIAN, YOSHIYUKI SAKAI, MARIE B. DEMAY, RENÉ ST-ARNAUD, and GLENVILLE JONES*

Department of Biochemistry (S.M., V.B, G.J.) Queen's University, Kingston (Ontario) Canada K7L 3N6; Genetics Unit (A.A., R.St-A.), Shriners Hospital for Children, Montreal (Quebec) Canada H3G 1A6; Departments of Medicine, Surgery, and Human Genetics (R.St-A.), McGill University, Montreal (Quebec) Canada H3A 2T5; and Endocrine Unit (Y.S., M.B.D.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA

* To whom correspondence should be addressed. E-mail: gj1{at}post.queensu.ca.

The 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) plays an important role in regulating concentrations of both the precursor 25-hydroxyvitamin D3 [25(OH)D3], and the hormone 1{alpha},25-dihydroxyvitamin D3 [1{alpha},25(OH)2D3]. Previous studies suggest that Cyp24a1 null mice cannot clear exogenous 1{alpha},25(OH)2D3 efficiently. Here, we examined the metabolic clearance in Cyp24a1 null mice in vivo and in vitro using a physiological dose of [1{beta}-3H]1{alpha},25(OH)2D3 or [26,27-methyl-3H]25(OH)D3. Cyp24a1 null mice showed difficulty in eliminating [1{beta}-3H]1{alpha},25(OH)2D3 from the bloodstream and tissues over a 96 h time course whereas heterozygotic mice eliminated the hormone within 6-12 h, though there was clearance of labeled hormone into water-soluble products involving liver in both genotypes. RT-PCR showed that Cyp24a1 null mice have decreased expression of 25-hydroxyvitamin D-1{alpha}-hydroxylase that must play a role in their survival. Following the administration of [26,27-methyl-3H]25(OH)D3, Cyp24a1 null mice showed higher [26,27-methyl-3H]25(OH)D3 levels and no [26,27-methyl-3H]24,25(OH)2D3 formation, while heterozygotic mice showed significant [26,27-methyl-3H]24,25(OH)2D3 production. Based upon in vitro experiments, keratinocytes from Cyp24a1 null mice fail to synthesize [1{beta}-3H]calcitroic acid from [1{beta}-3H]1{alpha},25(OH)2D3 or [26,27-methyl-3H]24,25(OH)2D3 from [26,27-methyl-3H]25(OH)D3 as do control mice, confirming the target cell catabolic role of CYP24A1 in these processes. Finally, the role of vitamin D receptor (VDR) in the vitamin D catabolic cascade was examined using VDR null mice. Keratinocytes from VDR null mice failed to metabolize [1{beta}-3H]1{alpha},25(OH)2D3 confirming the importance of vitamin D-inducible, VDR-mediated C24-oxidation pathway in target cells. These results suggest that the absence of CYP24A1 or VDR retards catabolism of 1{alpha},25(OH)2D3 and 25(OH)D3 reinforcing the physiological importance of CYP24A1 in vitamin D homeostasis.


Key words: Cytochrome P450; CYP24A1 • Vitamin D catabolism • 1{alpha} • 25-Dihydroxyvitamin D • Vitamin D receptor




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
J. Tan, P. P. Dwivedi, P. Anderson, B. K. Nutchey, P. O'Loughlin, H. A. Morris, B. K. May, A. Ferrante, and C. S. Hii
Antineoplastic agents target the 25-hydroxyvitamin D3 24-hydroxylase messenger RNA for degradation: implications in anticancer activity
Mol. Cancer Ther., December 1, 2007; 6(12): 3131 - 3138.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. E. Prosser, M. Kaufmann, B. O'Leary, V. Byford, and G. Jones
Single A326G mutation converts human CYP24A1 from 25-OH-D3-24-hydroxylase into -23-hydroxylase, generating 1{alpha},25-(OH)2D3-26,23-lactone
PNAS, July 31, 2007; 104(31): 12673 - 12678.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Masuda and G. Jones
Promise of vitamin D analogues in the treatment of hyperproliferative conditions.
Mol. Cancer Ther., April 1, 2006; 5(4): 797 - 808.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society